Tokyo Tape
Sign in
← Trans Genic

Quarterly report · Q3

2342.TEDINET S100STDC
Period2023-04-01 → 2023-12-31
Filed2024-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥9.7bn2023-04-01 → 2023-12-31Cons.Net sales
Revenue¥11.4bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥8.5bn2022-04-01 → 2022-12-31Cons.Net sales
Operating income¥52m2023-04-01 → 2023-12-31Cons.Operating income
Operating income¥153m2022-04-01 → 2022-12-31Cons.Operating income
Ordinary income¥51m2023-04-01 → 2023-12-31Cons.Ordinary income
Ordinary income¥199m2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥385m2022-04-01 → 2022-12-31Cons.Ordinary income
Profit before tax¥7m2023-04-01 → 2023-12-31Cons.Income before income taxes
Profit before tax¥344m2022-04-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)−¥38m2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥410m2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥182m2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income−¥43m2023-04-01 → 2023-12-31Cons.Profit loss
Net income¥171m2022-04-01 → 2022-12-31Cons.Profit loss
Total assets¥10.4bnat 2023-12-31Cons.Assets
Total assets¥10.7bnat 2023-03-31Cons.Assets
Total assets¥10.9bnat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥4.4bnat 2023-12-31Cons.Liabilities
Total liabilities¥4.6bnat 2023-03-31Cons.Liabilities
Net assets / equity¥6.0bnat 2023-12-31Cons.Net assets
Net assets / equity¥6.1bnat 2023-03-31Cons.Net assets
Net assets / equity¥6.7bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥2.8bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥3.5bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥-2.272023-04-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-5.152023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-24.322022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥10.812022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥7.542022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio56.7%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio56.4%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio60.4%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 32
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31−¥5m
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-12-31¥450,000
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31−¥5m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥152m
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥1.6bn
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥1.6bn
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥5m
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2023-04-01 → 2023-12-31−¥109m
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥8.1bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥8.1bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥760,000
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥313m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-12-31¥9.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-12-31¥9.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-12-31¥5m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-12-31¥204m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥4m
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-12-31¥2m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥6m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥157m
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥1.8bn
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥1.8bn
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥5m
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥132m
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥6.7bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥6.7bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥1m
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥179m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥8.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥8.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥6m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥310m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 361
ItemContextValueUnit
Subscription rights to sharesPrior1YearInstant200000JPY
Subscription rights to sharesCurrentQuarterInstant200000JPY
Non controlling interestsPrior1YearInstant104478000JPY
Non controlling interestsCurrentQuarterInstant100134000JPY
Net assetsPrior1YearInstant6122519000JPY
Net assetsCurrentQuarterInstant5968657000JPY
Liabilities and net assetsPrior1YearInstant10672931000JPY
Liabilities and net assetsCurrentQuarterInstant10354689000JPY
Net salesPrior1YTDDuration8464143000JPY
Net salesCurrentYTDDuration9743005000JPY
Cost of salesPrior1YTDDuration6826411000JPY
Cost of salesCurrentYTDDuration8079457000JPY
Gross profitPrior1YTDDuration1637731000JPY
Gross profitCurrentYTDDuration1663548000JPY
Selling general and administrative expensesPrior1YTDDuration1484425000JPY
Selling general and administrative expensesCurrentYTDDuration1611284000JPY
Operating incomePrior1YTDDuration153305000JPY
Operating incomeCurrentYTDDuration52263000JPY
Interest income noiPrior1YTDDuration420000JPY
Interest income noiCurrentYTDDuration57000JPY
Foreign exchange gains noiPrior1YTDDuration－JPY
Foreign exchange gains noiCurrentYTDDuration26532000JPY
Insurance income noiPrior1YTDDuration3214000JPY
Insurance income noiCurrentYTDDuration6430000JPY
Insurance premiums refunded cancellation noiPrior1YTDDuration367498000JPY
Insurance premiums refunded cancellation noiCurrentYTDDuration10635000JPY
Other noiPrior1YTDDuration10909000JPY
Other noiCurrentYTDDuration5650000JPY
Non operating incomePrior1YTDDuration382043000JPY
Non operating incomeCurrentYTDDuration49305000JPY
Interest expenses noePrior1YTDDuration20094000JPY
Interest expenses noeCurrentYTDDuration35817000JPY
Foreign exchange losses noePrior1YTDDuration19316000JPY
Foreign exchange losses noeCurrentYTDDuration－JPY
Acquisition expenses noePrior1YTDDuration81000000JPY
Acquisition expenses noeCurrentYTDDuration－JPY
Other noePrior1YTDDuration29966000JPY
Other noeCurrentYTDDuration15117000JPY
Non operating expensesPrior1YTDDuration150378000JPY
Non operating expensesCurrentYTDDuration50935000JPY
Ordinary incomePrior1YTDDuration384970000JPY
Ordinary incomeCurrentYTDDuration50633000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration10954000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration53000JPY
Extraordinary incomePrior1YTDDuration10954000JPY
Extraordinary incomeCurrentYTDDuration53000JPY
Impairment loss elPrior1YTDDuration47756000JPY
Impairment loss elCurrentYTDDuration－JPY
Loss on sales of noncurrent assets elPrior1YTDDuration300000JPY
Loss on sales of noncurrent assets elCurrentYTDDuration3110000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass